ProQR Therapeutics Capex To Revenue Over Time

PRQR Stock  USD 3.31  0.14  4.06%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ProQR Therapeutics Performance and ProQR Therapeutics Correlation.
  
As of 12/11/2024, Capex To Revenue is likely to drop to 0.20.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProQR Therapeutics. If investors know ProQR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProQR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.32)
Revenue Per Share
0.226
Quarterly Revenue Growth
1.906
Return On Assets
(0.15)
Return On Equity
(0.67)
The market value of ProQR Therapeutics is measured differently than its book value, which is the value of ProQR that is recorded on the company's balance sheet. Investors also form their own opinion of ProQR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ProQR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProQR Therapeutics' market value can be influenced by many factors that don't directly affect ProQR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProQR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProQR Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProQR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Capex To Revenue Analysis

Compare ProQR Therapeutics and related stocks such as Annexon, Arrowhead Pharmaceuticals, and Day One Biopharmaceu Capex To Revenue Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
ANNX0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
ARWR0.02983.26611.02289.81355.158724.38050.25210.0880.07110.13580.17040.2170.734239.839241.83
DAWN0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
TERN0.340.340.340.340.340.340.340.340.340.340.340.340.340.310.27
ALNY17.72160.01560.12510.08490.17720.31511.36891.1591.69390.63780.14280.09050.06950.0340.0323
WVE12.217112.217112.217112.217112.217112.21713.74885.09910.68950.24510.06660.01370.3730.00980.0093
BPMC0.42830.42830.42830.42830.42830.42830.08480.7240.28470.21070.0041.45070.04370.06440.0612
APLS0.02160.02160.02160.02160.02160.02160.02160.02160.02160.02160.02160.01660.02020.00190.0019
ASMB0.09590.09590.09590.09590.09590.09590.09590.09590.0230.09740.02810.4950.03560.0320.0304
SPRO2.47762.47762.47762.47762.47762.47762.47760.01360.61420.06620.01680.00210.00210.00250.0023
ACHL0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
TIL368368368368368368368368368368368368368331295
CTMX0.82430.82430.82430.82430.32760.20670.14470.02180.06370.06080.0230.02310.03270.00830.0079
NXTC0.53110.53110.53110.53110.53110.53110.53110.53110.53110.53110.31870.31870.31870.370.46
NUVB0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

ProQR Therapeutics and related stocks such as Annexon, Arrowhead Pharmaceuticals, and Day One Biopharmaceu Capex To Revenue description

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

My Equities

My Current Equities and Potential Positions

ProQR Therapeutics BV
PRQR
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationNetherlands
ExchangeNASDAQ Exchange
USD 3.31

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.